Yesterday, we reported on 2018 being a banner year for venture capital, but the New York Times says a movement of entrepreneurs is looking for other ways to raise money. . . . → Read More: Start-Ups Saying No Thanks to Venture Capital
|
|||||
|
|
Venture funding last year totaled $99.5 billion, the largest annual outlay since 2000. . . . → Read More: Infographic – Venture Finance Reaching Dot-Com Levels 
A company spun-off from a university medical materials lab received start-up funds to develop a non-opioid surgical pain therapy, including a clinical trial. . . . → Read More: Spin-Off Gains Seed Funds for Non-Opioid Pain Drug Drug maker Eli Lilly and Company is acquiring a developer of cancer therapies that target specific genetic alterations rather than tumors in the body. . . . → Read More: Lilly Buys Precision Cancer Company in $8B Deal 
We’ll check in from time to time on the Nasdaq Biotechnology Index that tracks 223 biotech industry stocks. . . . → Read More: Infographic – Nasdaq Biotech Index Recovers 
CB Insights recently issued its annual Tech IPO Report, showing the number of initial public stock offerings in the technology industries unchanged from 2017. . . . → Read More: Infographic – Tech IPOs Flat in 2018 
A 2 year-old company using computational techniques to find protein-targeting drugs raised $400 million in new financing, led by the venture funding arm of Softbank. . . . → Read More: Drug Discovery Start-Up Gains $400M Financing  Comments are closed  Finance  biomedical, biotechnology, chemistry, entrepreneurs, equity, investment, life sciences, mathematics, pharmaceuticals, physical sciences, physics, university, venture capital 
Eli Lilly and Co. is licensing a a treatment candidate for Alzheimer’s disease from biopharmaceutical company AC Immune that aims to block accumulation of tau proteins in the brain. . . . → Read More: Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal Comments are closed Intellectual property, Joint ventures/collaborations biomedical, clinical trials, equity, Europe, investment, licensing, life sciences, pharmaceuticals 
A start-up company developing nanoscale particles to deliver gene-editing enzymes, including those for Crispr, is raising $8.5 million in its seed funding round. . . . → Read More: Nanotech Gene Therapy Company Raises $8.5M in Seed Funds Comments are closed Finance, New products Asia, biomedical, biotechnology, engineering, entrepreneurs, equity, genomics, investment, life sciences, materials science, nanotechnology, pharmaceuticals, physical sciences, university 
Moderna Therapeutics, a biotechnology enterprise developing therapies with synthetic RNA, issued its initial public stock offering, or IPO, on Thursday, raising more than $604 million. . . . → Read More: RNA Biotech Raises $604M in IPO One comment - (Comments are closed) Finance biomedical, biotechnology, equity, genomics, investment, IPO, life sciences, pharmaceuticals |
||||
|
Copyright © 2019 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||